NCT03435796: Phase 2/3: Long-Term Follow-up for Participants Treated With Gene-Modified T Cells

NCT03435796: Phase 2/3: Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study.

Participants who received at least one GM T cell infusion will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.

Sponsor

Celgene

---

ClinicalTrials.gov Identifier: NCT03435796

Official Title: Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells

First Posted: February 19, 2018

Click here for details on ClinicalTrials.gov

---

Genetic: Gene-modified (GM) T cell therapy

---

Locations

United States, Alabama

United States, Arizona

United States, California

United States, Colorado

United States, Connecticut

United States, District of Columbia

United States, Florida

United States, Georgia

United States, Illinois

United States, Indiana

United States, Kansas

United States, Kentucky

United States, Maryland

United States, Massachusetts

United States, Michigan

United States, Minnesota

United States, Missouri

United States, Nebraska

United States, New Jersey

United States, New York

United States, North Carolina

United States, Ohio

United States, Oklahoma

United States, Oregon

United States, Pennsylvania

United States, South Carolina

United States, South Dakota

United States, Tennessee

United States, Texas

United States, Utah

United States, Virginia

United States, Washington

United States, Wisconsin

Canada, Alberta

Canada, British Columbia

Canada, Ontario

Canada, Quebec

Europe

United Kingdom

France

Germany

Italy

Netherlands

Spain

Austria

Belgium

Norway

Finland

Sweden

Switzerland

Asia

Japan